Edition:
India

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

556.10INR
24 Apr 2017
Change (% chg)

Rs-7.30 (-1.30%)
Prev Close
Rs563.40
Open
Rs563.75
Day's High
Rs563.80
Day's Low
Rs554.60
Volume
690,830
Avg. Vol
155,359
52-wk High
Rs621.90
52-wk Low
Rs458.25

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.50
Market Cap(Mil.): Rs454,105.69
Shares Outstanding(Mil.): 804.51
Dividend: 2.00
Yield (%): 0.35

Financials

  CIPL.BO Industry Sector
P/E (TTM): 45.67 29.09 30.04
EPS (TTM): 12.36 -- --
ROI: -- 13.81 13.33
ROE: -- 14.74 14.48

BUZZ-India's Cipla hits 3-1/2-month low, technicals signal further downside

** Drug maker Cipla Ltd falls as much as 1.98 pct to 562.7 rupees, to its lowest since Jan 3

21 Apr 2017

BRIEF-Cipla U.S. arm signs worldwide licensing deal with MEDRx

* Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments

06 Apr 2017

BRIEF-Medrx signs drug development and sale contract with Cipla USA Inc

* Says the company enters into a license contract with an India-based pharma Cipla Ltd's wholly owned US-based unit Cipla USA Inc, on development and sale of MRX-4TZT, transdermal patch for the treatment of spastic paralysis

06 Apr 2017

BRIEF-Cipla launches Hepatitis B vaccine in India

* Says Cipla launches Hepatitis B vaccine in India Source text - (http://bit.ly/2lUwkV6) Further company coverage:

17 Feb 2017

Cipla looks to boost US business as third-quarter profit beats estimates

MUMBAI Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market.

08 Feb 2017

BRIEF-Cipla Ltd Dec-qtr consol profit up about 44 pct

* Consol net profit in Dec quarter last year was 2.61 billion rupees as per Ind-AS; consol net sales was 30.70 billion rupees

08 Feb 2017

India's Cipla Q3 profit up 43.7 pct, tops estimates

MUMBAI, Feb 8 Indian drugmaker Cipla Ltd reported a 43.7 percent jump in third-quarter net profit, beating analysts' expectations.

08 Feb 2017

MEDIA-India's Cipla in talks to sell animal health unit - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

28 Nov 2016

MEDIA-India's Cipla plans to get more aggressive in US, UK - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

17 Nov 2016

Cipla Q2 profit falls as Europe, emerging markets suffer

MUMBAI Cipla Ltd, India's fifth-largest drugmaker by sales, on Wednesday reported a 35 percent fall in quarterly profit, missing analysts' estimates, mainly due to lower sales in the emerging markets and Europe.

09 Nov 2016

More From Around the Web

Earnings vs. Estimates